Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Roche plans $700m manufacturing plant in the US
Roche plans $700m manufacturing plant in the US
Roche is deepening its manufacturing footprint in the US with plans to invest more than $700m in a new production facility in Holly Springs, North Carolina, aimed at supporting its pipeline of next-ge...
Windtree Therapeutics Announces Presentation of Preclinical Data
Windtree Therapeutics Announces Presentation of Preclinical Data
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
HLS Therapeutics and Esperion partner
HLS Therapeutics and Esperion partner
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
FDA plans to expand unannounced inspections of foreign drug plants
FDA plans to expand unannounced inspections of foreign drug plants
The US Food and Drug Administration (FDA) is moving to tighten oversight of foreign manufacturers supplying the US market by subjecting overseas facilities to unannounced inspections, which ha...
Preclinical Data on First-in-Class BTK SH2
Preclinical Data on First-in-Class BTK SH2
Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous Urticaria
Takeda Pledges $30B in U.S., Argues Against Trump’s
Takeda Pledges $30B in U.S., Argues Against Trump’s
Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nations’ Proposal
Aptevo Therapeutics Provides Program Update for Bispecific APVO711 ( PD-L1 х CD40)
Aptevo Therapeutics Provides Program Update for Bispecific APVO711 ( PD-L1 х CD40)
Aptevo Therapeutics Provides Program Update for Bispecific APVO711 ( PD-L1 х CD40) that Combines a Checkpoint Inhibitor and Immune Activation
Sanofi exec tells biotechs not to scrimp on clinical trial design
Sanofi exec tells biotechs not to scrimp on clinical trial design
It is vital for biotech companies to run the right clinical trial and not cut costs with trial design or patient recruitment, the executive said.
AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use
AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use
AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved by the European Commission (EC) as part o...
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand